Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant oxaliplatin plus fluoropyrimidine chemoradiation in locally advanced rectal cancer
2006-002385-20Phase 3Completed
- Sponsor
- Universitätsklinikum Erlangen
- Start
- May 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxaliplatin in rectal cancer (2 arms), sponsored by Universitätsklinikum Erlangen. Primary endpoint: Disease-free survival at 3 years. Started May 2006; status: completed.
02
Drugs
oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2006-002385-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002385-20.